We are live on ! Find out more
PPH icon

VanEck Pharmaceutical ETF
PPH

51 hedge funds and large institutions have $98.3M invested in VanEck Pharmaceutical ETF in 2016 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 15 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 13

14.95% less ownership

Funds ownership: 52.45% → 37.51% (-15%)

15% less funds holding

Funds holding: 60 → 51 (-9)

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

45% less capital invested

Capital invested by funds: $177M → $98.3M (-$79.2M)

Holders
51
Holders Change
-9
Holders Change %
-15%
% of All Funds
1.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
11
Increased
15
Reduced
13
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JP Morgan Chase
JP Morgan Chase
New York
+$13.4M
2
Bank of America
Bank of America
North Carolina
+$4.87M
3
UBS Group
UBS Group
Switzerland
+$4.2M
4
CC
Colrain Capital
Massachusetts
+$2.44M
5
Morgan Stanley
Morgan Stanley
New York
+$1.46M

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$66.8M
2
Citigroup
Citigroup
New York
-$16M
3
LFM
Lumina Fund Management
New York
-$3.7M
4
VF
Virtu Financial
New York
-$2.32M
5
AL
Aspiriant LLC
California
-$1.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$268K +$5.34K +100 +2%
MIM
27
Macroview Investment Management
Maryland
$234K -$55.2K -1,034 -19%
FPCM
28
Financial Partners Capital Management
New York
$234K -$12K -225 -5%
TSS
29
Two Sigma Securities
New York
$224K +$16.2K +303 +8%
FMW
30
Farr Miller & Washington
District of Columbia
$210K – – –
MFS
31
MSI Financial Services
Massachusetts
$164K -$57.9K -1,084 -26%
Bank of Montreal
32
Bank of Montreal
Ontario, Canada
$153K – – –
MA
33
MUFG Americas
New York
$63K – – –
TCM
34
Tradewinds Capital Management
Washington
$63K – – –
HCM
35
Highlander Capital Management
New Jersey
$57K – – –
GT
36
Glenmede Trust
Pennsylvania
$52K – – –
EDRH
37
Edmond de Rothschild Holding
Switzerland
$21K – – –
IP
38
Intellectus Partners
California
$18K +$18.7K +350 New
CPA
39
Clear Perspective Advisors
Illinois
$16K +$16K +300 New
NSIM
40
North Star Investment Management
Illinois
$9K -$40.8K -764 -81%
TRCT
41
Tower Research Capital (TRC)
New York
$9K -$14.7K -275 -62%
ADL
42
Asset Dedication LLC
California
$9K +$8.98K +168 New
IA
43
IFP Advisors
Florida
$8K – – –
US Bancorp
44
US Bancorp
Minnesota
$8K +$4.49K +84 +127%
Fifth Third Bancorp
45
Fifth Third Bancorp
Ohio
$8K +$7.75K +145 New
WEC
46
Winslow Evans & Crocker
Massachusetts
$5.25K – – –
Carson Wealth (CWM LLC)
47
Carson Wealth (CWM LLC)
Nebraska
$5K – – –
PMFA
48
Plante Moran Financial Advisors
Michigan
$5K +$5.34K +100 New
WA
49
WFG Advisors
Texas
$5K +$5.34K +100 New
AG
50
Advisor Group
Arizona
$2K -$962 -18 -30%
1
2
3

PPH Hedge Fund Activity: Q4 2016 in Review

51 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in VanEck Pharmaceutical ETF (PPH) for Q4 2016, worth a combined $98.3M — down 45% from $177M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of PPH and 11 opened new positions — a net loss of 6 holders — while 13 trimmed existing stakes and 15 added.

The largest buyer was JP Morgan Chase, adding an estimated $13.4M. The largest seller was Goldman Sachs, cutting an estimated $66.8M.

  • 51 institutional investors held VanEck Pharmaceutical ETF (PPH) as of Q4 2016, down from 60 in Q3 2016.
  • Funds reported $98.3M of VanEck Pharmaceutical ETF stock for Q4 2016, down 45% quarter-over-quarter.
  • 11 funds opened new VanEck Pharmaceutical ETF positions in Q4 2016 and 17 closed out, a net change of -6 holders.
  • The largest VanEck Pharmaceutical ETF buyer in Q4 2016 was JP Morgan Chase, an estimated $13.4M added.
  • The largest VanEck Pharmaceutical ETF seller in Q4 2016 was Goldman Sachs, an estimated $66.8M sold.

Based on aggregated 13F filings for Q4 2016.